Published in:
Open Access
01-03-2012 | Year in Review 2011
Year in review in Intensive Care Medicine 2011. II. Cardiovascular, infections, pneumonia and sepsis, critical care organization and outcome, education, ultrasonography, metabolism and coagulation
Authors:
Massimo Antonelli, Marc Bonten, Jean Chastre, Giuseppe Citerio, Giorgio Conti, J. Randall Curtis, Daniel De Backer, Goran Hedenstierna, Michael Joannidis, Duncan Macrae, Jordi Mancebo, Salvatore M. Maggiore, Alexandre Mebazaa, Jean-Charles Preiser, Patricia Rocco, Jean-François Timsit, Jan Wernerman, Haibo Zhang
Published in:
Intensive Care Medicine
|
Issue 3/2012
Login to get access
Excerpt
Mebazaa and colleagues in two interesting papers [
1,
2] described the clinical presentation, management, and outcomes of acute heart failure (AHF) through the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF) on AHF conducted in nine countries in four continents. In the first paper [
1] data from 4,953 patients with AHF were collected via questionnaire from 666 hospitals. Clinical presentation included decompensated congestive HF (38.6%), pulmonary edema (36.7%), and cardiogenic shock (11.7%). Patients with a de novo episode of AHF (36.2%) were younger, had less comorbidities and lower blood pressure despite greater left ventricular ejection fraction (LVEF), and were more often admitted to ICU. Overall, intravenous (IV) diuretics were given in 89.7%, vasodilators in 41.1%, and inotropic agents (dobutamine, dopamine, adrenaline, noradrenaline, and levosimendan) in 39% of cases. Hospital death rate was 12%, the majority due to cardiogenic shock (43%). More patients with de novo AHF (14.2%) than patients with a pre-existing episode of AHF (10.8%) (
p = 0.0007) died. There was graded mortality in intensive care unit (ICU), critical care unit (CCU), and ward patients with mortality in ICU patients being the highest (17.8%) (
p < 0.0001). The conclusion stressed the concept that the recognition of subgroups might improve management and outcome by defining specific therapeutic requirements. …